La maladie de Rendu-Osler (télangiectasie hémorragique héréditaire)
Revue des Maladies Respiratoires · 2023-05 · 40 (5) · 391-405
DOI: 10.1016/j.rmr.2023.02.007 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Revue des Maladies Respiratoires, 2023-05. Verfasst von A Parrot und 10 weiteren Autor:innen. Beteiligte Einrichtung: Service de pneumologie, centre de compétence de la maladie de Rendu-Osler, hôpital Tenon, AP-HP, 75020 Paris, France. Electronic address: antoine.par…. Hauptthemen laut MEDLINE: Telangiectasia, Hereditary Hemorrhagic, Arteriovenous Malformations. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 98 Literaturangaben.
Abstract (Originalsprache)
Hereditary hemorrhagic telangiectasia, also known as Rendu-Osler - Weber disease, is a rare, autosomal dominant vascular disease, with prevalence of 1/5,000. The condition is characterized by muco-cutaneous telangiectasias, which are responsible for a hemorrhagic syndrome of variable severity, as well as arteriovenous malformations (AVMs) appearing in the lungs, the liver, and the nervous system. They can be the source of shunts, which may be associated with high morbidity (neurological ischemic stroke, brain abscess, high-output heart failure, biliary ischemia…). It is therefore crucial to establish a clinical diagnosis using the Curaçao criteria or molecular diagnosis based on genetic analysis of the ENG, ACVRL1, SMAD4 and GDF2 genes. In most cases, multidisciplinary management allows patients to have normal life expectancy. Advances in interventional radiology and better understanding of the pathophysiology of angiogenesis have resulted in improved therapeutic management. Anti-angiogenic treatments, such as bevacizumab (BVZ, an anti-VEGF antibody), have proven to be effective in cases involving bleeding complications and severe liver damage with cardiac repercussions. Other anti-angiogenic agents are currently being investigated, including tyrosine kinase inhibitors.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Service de pneumologie, centre de compétence de la maladie de Rendu-Osler, hôpital Tenon, AP-HP, 75020 Paris, France. Electronic address: antoine.parrot@aphp.fr.
- Service de radiologie, hôpital Tenon, AP-HP, 75020 Paris, France; UFR médecine, Sorbonne université, 75006 Paris, France.
- Service de gastroentérologie, hôpital Tenon, AP-HP, 75020 Paris, France.
- Service de médecine interne, hôpital Tenon, AP-HP, 75020 Paris, France.
- Service d'ORL, hôpital Tenon, AP-HP, 75020 Paris, France.
- Service de génétique, hôpital de la Pitié-Salpetrière, AP-HP, 75020 Paris, France.
Zitieren
APA
Parrot, A., Barral, M., Amiot, X., Bachmeyer, C., Wagner, I., Eyries, M., Alamowitch, S., Ederhy, S., Epaud, R., Dupuis-Girod, S., & Cadranel, J. (2023). La maladie de Rendu-Osler (télangiectasie hémorragique héréditaire). Revue des Maladies Respiratoires, 40(5), 391-405. https://doi.org/10.1016/j.rmr.2023.02.007
Vancouver
Parrot A, Barral M, Amiot X, Bachmeyer C, Wagner I, Eyries M, et al. La maladie de Rendu-Osler (télangiectasie hémorragique héréditaire). Revue des Maladies Respiratoires. 2023;40(5):391-405. doi:10.1016/j.rmr.2023.02.007
BibTeX
@article{Parrot2023,
author = {Parrot, A and Barral, M and Amiot, X and Bachmeyer, C and Wagner, I and Eyries, M and Alamowitch, S and Ederhy, S and Epaud, R and Dupuis-Girod, S and Cadranel, J},
title = {La maladie de Rendu-Osler (télangiectasie hémorragique héréditaire)},
journal = {Revue des Maladies Respiratoires},
year = {2023},
volume = {40},
number = {5},
pages = {391--405},
doi = {10.1016/j.rmr.2023.02.007}
}
EUVIMED